NasdaqGS:REPLBiotechs
Replimune Group (REPL) Stock Looks Pricey On Book Value Despite 199% Returns
Replimune Group stock has delivered a very strong 199.4% return over the past year, yet the broader valuation checks still flag the shares as leaning expensive rather than a clear bargain.
Over the last 12 months, Replimune Group has returned 199.4%, which puts extra focus on whether the recent share price strength is already baking in optimistic expectations.
The FDA advisory panel endorsement of RP1 for advanced melanoma can support higher growth expectations for the business, while...